Sign In
Buy COYA
$4.19
+0.110 (+2.70%)
At Close: Jul 31, 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
08:15am, Tuesday, 11'th Jun 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Tr
Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer
02:55pm, Monday, 10'th Jun 2024
Coya Therapeutics is set to initiate a Phase 2 trial in ALS and release the topline results of a Phase 2 trial in Alzheimer's disease in the summer. The company's anti-inflammatory approach has receiv
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
08:15am, Monday, 03'rd Jun 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Tr
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
08:15am, Tuesday, 28'th May 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
7 Biotech Stocks to Put on Your Breakthrough Radar
12:32pm, Monday, 27'th May 2024
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way fir
Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment
03:40pm, Thursday, 23'rd May 2024
Coya Therapeutics (COYA) is a clinical-stage company focused on developing multi-modality Treg therapies. CEO Howard Berman joins Nicole Petallides to give an overview of the company.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
08:15am, Monday, 20'th May 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
04:10pm, Thursday, 09'th May 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases
06:45am, Wednesday, 01'st May 2024
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases, with their leading treatment, COYA 302, targeting a market potential of over $10 billion. COYA's pipeline in
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
08:15am, Friday, 26'th Apr 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
08:15am, Monday, 22'nd Apr 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
08:15am, Thursday, 18'th Apr 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
